Originally developed to treat diabetes, a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are ...

A novel mu-opioid receptor agonist showed strong analgesia without respiratory depression, tolerance, or significant ...

For many people, maintaining a balanced diet and exercising regularly does not lead to significant weight loss. And that's ...

Combat muscle loss with this 7-move routine.

Among patients with AD, GLP-1 RAs reduced the risk for various MACE outcomes, including heart failure, cerebrovascular disease, and more.

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...

ROANOKE, Va. (WDBJ) - Southwest Virginia was ground zero for the opioid epidemic. Even though overdose deaths have fallen ...

WHO updates guidelines on opioid dependence treatment and overdose prevention: Geneva Monday, April 6, 2026, 14:00 Hrs [IST] WHO announces the update of several recommendations in ...

Sam Chun Dang Pharm, once the top market-cap company on Korea’s Kosdaq driven by optimism over its oral insulin and obesity ...

In a notable update, WHO has expanded its guidance to include long-acting injectable formulations of buprenorphine, issuing a conditional recommendation for their use.

Modest real-world weight loss may significantly reduce a person’s risk for cancer, according to results of a retrospective ...

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing ...